Purevax FeLV
vaccine against feline leukaemia
Table of contents
Overview
Purevax FeLV is a veterinary vaccine used to treat feline leukaemia in cats. It contains the active substance recombinant live canarypox virus (vCP97).
Purevax FeLV is used to vaccinate cats from the age of eight weeks against feline leukaemia, an illness affecting the immune system caused by a type of virus known as a retrovirus. The vaccine is used to prevent the symptoms of the disease and to prevent FeLV from remaining in the blood.
Authorisation details
Product details | |
---|---|
Name |
Purevax FeLV
|
Agency product number |
EMEA/V/C/000056
|
Active substance |
feline leukaemia virus recombinant canarypox virus (vCP97)
|
International non-proprietary name (INN) or common name |
vaccine against feline leukaemia
|
Species |
Cats
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI06AD
|
Publication details | |
---|---|
Marketing-authorisation holder |
Boehringer Ingelheim Vetmedica GmbH
|
Revision |
12
|
Date of issue of marketing authorisation valid throughout the European Union |
13/04/2000
|
Contact address |
Binger Strasse 173 |
Product information
14/08/2020 Purevax FeLV - EMEA/V/C/000056 - IB-0028
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Immunologicals for felidae
Therapeutic indication
Active immunisation of cats of 8 weeks of age or older against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease.
Onset of immunity has been demonstrated 2 weeks after primary vaccination course.
The duration of immunity is one year after the last vaccination.